Paul Barrow joins CiToxLAB
pharmafile | July 14, 2011 | Appointment | Research and Development | appointment, research and development
French CRO CiToxLAB has appointed Paul Barrow as director of scientific projects and client consulting.
He joins the Evreux-based company, which specialises in non-clinical research, from Ricerca Biosciences where he spent ten years as a director of toxicology.
In total Paul has more than 30 years’ experience in preclinical safety testing, gained through working for the pharmaceutical industry and CROs in France, the UK and Italy.
CiToxLAB said his appointment would increase its attractiveness in reprotoxicology and juvenile studies.
Sophie Baratte, managing director of CiToxLAB France, said: “I am delighted that we are adding a colleague of this standard to our organization. Paul will bring further expertise and credibility to the CIT brand that has been established over the last 40 years.”
The CiToxLAB Group was created through the merger of CiT and LAB Research and offers a range of pre-clinical and specialty safety evaluation services from four facilities in France, Canada, Denmark and Hungary.
Related Content

PlasmidFactory founder Dr. Martin Schleef honoured with the NRW Innovation Award 2025
The founder and long-standing CEO of PlasmidFactory, Dr. Martin Schleef, was honoured in Düsseldorf with …

AAX Biotech announces collaboration for cardiovascular antibody therapy
Swedish biotech firm AAX Biotech has entered a new collaboration focused on the development of …

Research finds tablet effective in slowing progression of Alzheimer’s disease over 18 months
TauRx Pharmaceutics reports that hydromethylthionine mesylate (HMTM) could be an oral treatment for slowing the …






